

**In the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

1. (Currently Amended) A pharmaceutical composition ~~for use as an immunostimulant comprising a polycationic carbohydrate or a pharmaceutically acceptable derivative thereof, wherein the polycationic carbohydrate comprises~~ is a water-soluble alkylated chitosan, selected from the group consisting of trimethyl chitosan and N-carboxymethyl chitosan or a ~~pharmaceutically acceptable~~ salt or derivative thereof, ~~or a mixture thereof.~~
2. Cancelled.
3. (Currently Amended) The pharmaceutical composition polycationic carbohydrate of claim “1” 1 wherein the alkylated chitosan is trimethylchitosan.
4. (Previously Presented) The pharmaceutical composition of claim 1, further comprising a biologically active agent which is capable of generating a protective immune response in an animal.
5. (Previously Presented) The pharmaceutical composition of claim 1 further comprising a cationic polypeptide, cationic polyamino acid, a quaternary ammonium compound or a mixture thereof.
6. (Currently Amended) The pharmaceutical composition of claim “1” 1 further comprising a first material capable of forming particles, wherein the pharmaceutical composition is in the form of particles.

7-10. Cancelled.

11. (Previously Presented) The composition of claim 6 wherein the particles comprise microspheres, microparticles or liposomes.

12. (Previously Presented) The composition of claim 11 wherein the particles are microparticles.

13. (Previously Presented) The composition of claim 6 wherein the first material capable of forming particles is a polymeric material which has a molecular weight of 100kDa or more.

14. (Previously Presented) The composition of claim 6 wherein the first material capable of forming particles comprises poly-(L-lactide).

15. (Previously Presented) The composition of claim 6 wherein the ratio of the first material capable of forming particles to the polycationic carbohydrate is from 99:1 to 9:1 w/w.

16. (Currently Amended) The composition of claim “37” 37 wherein the biologically active agent is capable of generating a protective immune response against tetanus, diphtheria, or *Yersinia pestis*.

17. (Previously Presented) The composition of claim 16 wherein the biologically active agent comprises a combination of the V antigen of *Y. pestis* or an immunologically active fragment thereof, and the F1 antigen of *Y. pestis* or an immunologically active fragment thereof.

18. (Previously Presented) The composition of claim 6 which is adapted for intranasal application.

19. (Previously Presented) The composition of claim 6 which is adapted for parenteral administration.

20. (Previously Presented) The composition of claim 6 which further comprises a chemical compound selected from the group consisting of:

- (A) a polyamino acid,
- (B) a vitamin or vitamin derivative,
- (C) cationic pluronics,
- (D) a clathrate,
- (E) a complexing agent,
- (F) cetrimides,
- (G) an S-layer protein, or
- (H) methyl-glucamine.

21. (Currently Amended) The composition of claim “1” further comprising a cationic plronic.

22. (Previously Presented) The composition of claim 20 which comprises particles of the cationic plronic which are surface modified with the polycationic carbohydrate.

23-35. Cancelled.

36. (Previously Presented) The composition of claim 6, wherein the polycationic carbohydrate is distributed throughout the particles including at the surface.

37. (Previously Presented) The composition of claim 6, which further comprises a biologically active agent which is able to produce an immune response in an animal to which it is administered.

38-39. Cancelled.